Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLCS | P50747 | 3/20 | 0.49 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | HINT1 | P49773 | 1/20 | 0.42 |
| ▸ | FGF1 | P05230 | 1/20 | 0.41 |
| ▸ | FGF2 | P09038 | 1/20 | 0.41 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.41 |
| ▸ | DTYMK | P23919 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22897369 | 0.92 | HLCS (0.47) | HLCSPLCD1F2HINT1FGF1 | |
| SCHEMBL29592014 | 0.91 | PLCD1 (0.44) | HLCSPLCD1F2HINT1 | |
| SCHEMBL20129500 | 0.91 | F2 (0.47) | HLCSPLCD1F2FGF1FGF2 | |
| SCHEMBL22192980 | 0.91 | HLCS (0.46) | HLCSPLCD1F2HINT1FGF1 | |
| SCHEMBL20126980 | 0.91 | F2 (0.47) | HLCSPLCD1F2FGF1FGF2 | |
| SCHEMBL20130787 | 0.90 | PLCD1 (0.48) | HLCSPLCD1F2FGF1FGF2 | |
| SCHEMBL20417307 | 0.86 | POLB (0.42) | DTYMK | |
| SCHEMBL20417316 | 0.86 | POLB (0.42) | DTYMK | |
| SCHEMBL22623187 | 0.86 | HLCS (0.41) | HLCSF2HINT1 | |
| SCHEMBL20234146 | 0.85 | PLCD1 (0.46) | HLCSPLCD1F2HINT1FGF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795492-B2 | Methods of nucleic acid sample preparation | ArcherDX, LLC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795492-B2 | Methods of nucleic acid sample preparation | ArcherDX, LLC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4198140-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION FOR IMMUNE REPERTOIRE SEQUENCING | ArcherDX, LLC (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20210180118-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION FOR IMMUNE REPERTOIRE SEQUENCING | ARCHERDX, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210054435-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION | ArcherDX, Inc. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10704082-B2 | Methods of nucleic acid sample preparation | ArcherDX, Inc. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10683531-B2 | Methods of nucleic acid sample preparation for analysis of cell-free DNA | ArcherDX, Inc. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180127807-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION FOR ANALYSIS OF CELL-FREE DNA | ArcherDX, Inc. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127806-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION | ArcherDX, Inc. (US) | 2018-05-10 | — | — | US | disclosed |
| WO-2018053362-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION | ArcherDX, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053365-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION FOR ANALYSIS OF CELL-FREE DNA | ArcherDX, Inc. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210180118-A1 | METHODS OF NUCLEIC ACID SAMPLE PREPARATION FOR IMMUNE REPERTOIRE SEQUENCING | TLR9, HAVCR2, IGSF11 | HLCS 1870/4885PLCD1 2982/4885F2 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.